Title |
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
|
---|---|
Published in |
Nature Medicine, October 2014
|
DOI | 10.1038/nm.3708 |
Pubmed ID | |
Authors |
Antonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, Kariman Chaba, David P Enot, Julien Adam, Ilio Vitale, Aicha Goubar, Elisa E Baracco, Catarina Remédios, Laetitia Fend, Dalil Hannani, Laetitia Aymeric, Yuting Ma, Mireia Niso-Santano, Oliver Kepp, Joachim L Schultze, Thomas Tüting, Filippo Belardelli, Laura Bracci, Valentina La Sorsa, Giovanna Ziccheddu, Paola Sestili, Francesca Urbani, Mauro Delorenzi, Magali Lacroix-Triki, Virginie Quidville, Rosa Conforti, Jean-Philippe Spano, Lajos Pusztai, Vichnou Poirier-Colame, Suzette Delaloge, Frederique Penault-Llorca, Sylvain Ladoire, Laurent Arnould, Joanna Cyrta, Marie-Charlotte Dessoliers, Alexander Eggermont, Marco E Bianchi, Mikael Pittet, Camilla Engblom, Christina Pfirschke, Xavier Préville, Gilles Uzè, Robert D Schreiber, Melvyn T Chow, Mark J Smyth, Enrico Proietti, Fabrice André, Guido Kroemer, Laurence Zitvogel |
Abstract |
Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell-mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate the rapid production of type I interferons (IFNs) by malignant cells after activation of the endosomal pattern recognition receptor Toll-like receptor 3 (TLR3). By binding to IFN-α and IFN-β receptors (IFNARs) on neoplastic cells, type I IFNs trigger autocrine and paracrine circuitries that result in the release of chemokine (C-X-C motif) ligand 10 (CXCL10). Tumors lacking Tlr3 or Ifnar failed to respond to chemotherapy unless type I IFN or Cxcl10, respectively, was artificially supplied. Moreover, a type I IFN-related signature predicted clinical responses to anthracycline-based chemotherapy in several independent cohorts of patients with breast carcinoma characterized by poor prognosis. Our data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens. We surmise that such 'viral mimicry' constitutes a hallmark of successful chemotherapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 2 | 11% |
United Kingdom | 2 | 11% |
United States | 1 | 6% |
Armenia | 1 | 6% |
Belgium | 1 | 6% |
New Zealand | 1 | 6% |
Canada | 1 | 6% |
Unknown | 9 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 14 | 78% |
Science communicators (journalists, bloggers, editors) | 2 | 11% |
Scientists | 2 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | <1% |
Spain | 3 | <1% |
France | 1 | <1% |
Norway | 1 | <1% |
Australia | 1 | <1% |
Germany | 1 | <1% |
Italy | 1 | <1% |
United Kingdom | 1 | <1% |
Unknown | 661 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 140 | 21% |
Researcher | 134 | 20% |
Student > Master | 62 | 9% |
Student > Doctoral Student | 42 | 6% |
Student > Bachelor | 39 | 6% |
Other | 122 | 18% |
Unknown | 136 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 134 | 20% |
Agricultural and Biological Sciences | 122 | 18% |
Medicine and Dentistry | 104 | 15% |
Immunology and Microbiology | 85 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 17 | 3% |
Other | 47 | 7% |
Unknown | 166 | 25% |